Hyperglycemia Enhances Immunosuppression and Aerobic Glycolysis of Pancreatic Cancer Through Upregulating Bmi1-UPF1-HK2 Pathway

Cell Mol Gastroenterol Hepatol. 2022;14(5):1146-1165. doi: 10.1016/j.jcmgh.2022.07.008. Epub 2022 Jul 19.

Abstract

Background & aims: Accumulating evidence strongly suggests that hyperglycemia promotes the progression of pancreatic cancer (PC). Approximately 80% of patients with PC are intolerant to hyperglycemic conditions. In this study, we define the role of Bmi1, a stemness-related oncogene, in controlling the Warburg effect, and immune suppression under hyperglycemia conditions.

Methods: The diabetes mellitus model was established by intraperitoneal injection of streptozotocin. The role of the hyperglycemia-Bmi1-HK2 axis in glycolysis-related immunosuppression was examined in both orthotopic and xenograft in vivo models. Evaluation of immune infiltrates was carried out by flow cytometry. Human PC cell lines, SW1990, BxPC-3, and CFPAC-1, were used for mechanistic in vitro studies.

Results: Through bioinformatics analysis, we found that hyperglycemia was strongly related to aerobic glycolysis, immunosuppression, and cancer cell stemness. High glucose condition in the tumor microenvironment promotes immune suppression by upregulating glycolysis in PC cells, which can be rescued via knockdown Bmi1 expression or after 2-deoxy-D-glucose treatment. Through gain-/loss-of-function assessments, we found that Bmi1 upregulated the expression of UPF1, which enhanced the stability of HK2 mRNA and thereby increased the expression of HK2. The role of the hyperglycemia-Bmi-HK2 pathway in the inhibition of antitumor immunity was further verified via the immune-competent and immunodeficient mice model. We also demonstrated that hyperglycemia promotes the expression of Bmi1 by elevating the intracellular acetyl-CoA levels and histone H4 acetylation levels.

Conclusions: Our results suggest that the previously unreported Bmi1-UPF1-HK2 pathway contributes to PC progression and immunosuppression, which may bring in new targets for developing effective therapies to treat patients with PC.

Keywords: Aerobic Glycolysis; Bmi1; Hyperglycemic; Immunosuppression; Tumor Immune Microenvironment; Tumor Stemness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetyl Coenzyme A / metabolism
  • Animals
  • Deoxyglucose
  • Glucose
  • Glycolysis / genetics
  • Histones / metabolism
  • Humans
  • Hyperglycemia*
  • Immunosuppression Therapy
  • Mice
  • Mice, Nude
  • Pancreatic Neoplasms* / genetics
  • Polycomb Repressive Complex 1 / genetics
  • Polycomb Repressive Complex 1 / metabolism
  • RNA, Messenger / genetics
  • Streptozocin
  • Tumor Microenvironment

Substances

  • Streptozocin
  • Acetyl Coenzyme A
  • Histones
  • RNA, Messenger
  • Glucose
  • Deoxyglucose
  • BMI1 protein, human
  • Polycomb Repressive Complex 1
  • UPF1 protein, human
  • Bmi1 protein, mouse